24 August 2018: vol 19 no 14: AIDS 2018 – next reports…

22nd International AIDS Conference (AIDS 2018) – second reports

Namibia close to achieving 90-90-90 targets

Dolutegravir monotherapy: still no longer recommended in either research or clinical practice

Changing comorbidities in HIV positive people older than 60 at London clinic

High acceptability of annual digital (finger) exam for early detection of anal cancer in gay men >35 years old

High rates of anal HPV infection in gay men using PrEP in IPERGAY: the role of vaccination

HCV incidence and reinfection in HIV negative gay men using PrEP in the Netherlands

FDA-approved compounds that might selectively reverse HIV latency

Lack of impact on viral reservoir with α4β7 monoclonal antibody vedolizumab: macaque results not matched in humans

Janssen HIV vaccine: update from APPROACH and largescale efficacy study

Viral load testing in Latin America and the Caribbean

Access to viral load testing increased from 14% to 61% over two years in Côte d’Ivoire

Resolving a diagnosis for people with persistently indeterminate HIV test results

10th International Workshop on HIV Paediatrics – second reports

Dolutegravir dispersible tablets for infants and young children: early PK, safety and efficacy

Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections

Interactions between oral anticoagulants and Genvoya, Stribild and cobicistat: FDA label updates

More than ten people a day died from drug-related deaths in England and Wales last year:

We learn, we think, we change: Martin Fisher Foundation and Stiggy launch campaign to end stigma

24 August 2018: vol 19 no 14

03 August 2018: vol 19 no 13: AIDS 2018 – first reports

22nd International AIDS Conference (AIDS 2018) – first reports

Caution on press conference news from AIDS 2018

Zero HIV transmissions in PARTNER 2 study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV

DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study

Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study  

Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil 

WHO recommends dolutegravir widely but women’s access will depend on contraception provision (2018)

No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)

Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN-1

First randomised kick-and-kill cure study fails to reduce HIV reservoir: RIVER study reports vorinostat and vaccines show activity, but not enough

Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen

Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians

AIDS 2018 online: links to selected webcasts

10th International Workshop on HIV Paediatrics – first reports

Preconception safety signal with dolutegravir: data from the Tsepamo study

03 August 2018: vol 19 no 13

Fit for purpose: Antiretroviral treatment optimisation July 2018

Fit for purpose 2018 – PDF

What to watch: HIV cure-related research at AIDS 2018

HIV pipeline 2018: full version

11 July 2018: vol 19 no 12: DTG and preconception – special report

Dolutegravir preconception signal: time is up for shoddy surveillance

AIDS 2018: Programme online and late-breaker highlights announced three weeks before the conference

Bictegravir/FTC/TAF (Biktarvy) approved in Europe

Dolutegravir: need to consider all pros and cons before switching in pregnancy

Why U=U does not apply to breastfeeding

11 July 2018: vol 19 no 12

29 June 2018: vol 19 no 11: darunavir/cobicistat alert and PK reports

New contraindication against using darunavir/cobicistat during pregnancy

Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore

Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model

Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole  

Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network  

Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults 

No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin  

Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin

Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort

China approves albuvirtide: a once-weekly injectable entry inhibitor

Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance

New FDA guidance for developing PrEP drugs

UK PrEP IMPACT trial announces 3000 new places for gay men but low uptake by women, African and transgender people

RITA: issue on lung health

Post navigation